Patents by Inventor Boris N. Reznik

Boris N. Reznik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230413806
    Abstract: Described are means, methods and compositions of matter useful for enhancing quality of organ transplants by induction of postmortem regeneration. The disclosure provides administration of regenerative cells and/or factors in a brain dead recipient whose body is maintained in a viable state by life supporting machinery.
    Type: Application
    Filed: June 21, 2023
    Publication date: December 28, 2023
    Inventors: Thomas E. ICHIM, Kalina O'CONNOR, Boris N. REZNIK
  • Patent number: 8263571
    Abstract: The present invention provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: September 11, 2012
    Assignee: Vendevia Group, LLC
    Inventors: Boris N. Reznik, Christopher J. Dougherty, Thomas Ichim
  • Publication number: 20100279291
    Abstract: The present invention provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.
    Type: Application
    Filed: August 11, 2008
    Publication date: November 4, 2010
    Applicant: VENDEVIA GROUP, LLC
    Inventors: Boris N. Reznik, Christopher J. Dougherty, Thomas Ichim
  • Publication number: 20090169613
    Abstract: The present invention provides compositions useful for the treatment of cancer that inhibit tumor stem cells through suppression of an activity or the expression of BORIS. The compositions target tumor stem cells through molecules that are specific to tumor stem cells. Specifically, the invention provides immunoliposomes specific to tumor stem cells that include nucleic acid compositions capable of eliciting the process of RNA interference of BORIS expression. Also provided are immunoliposomes specific to tumor stem cells that include anti-BORIS ribozymes, antisense oligonucleotides, decoy oligonucleotides or small molecule inhibitors. Methods of manufacturing, delivering, and use of such compositions in the treatment of cancer are also provided.
    Type: Application
    Filed: November 10, 2008
    Publication date: July 2, 2009
    Inventors: Boris N. Reznik, Thomas Ichim, Christopher Dougherty
  • Publication number: 20090081245
    Abstract: Disclosed are methods and compositions for developing mutants of the Brother of the Regulator of Imprinted Sites (BORIS) suitable for immunotherapeutic purposes. Said methods involve the mutagenesis and/or deletion of various sequences within wild-type BORIS protein with the objected aim of constructing nucleic acids and proteins encoded by said nucleic acids capable of eliciting immune responses while concurrently lacking oncogenicity. Methods of screening of small molecule inhibitors of wild-type BORIS activity are also provided.
    Type: Application
    Filed: September 8, 2008
    Publication date: March 26, 2009
    Inventors: Boris N. Reznik, Christopher J. Dougherty, Thomas Ichim